multiple sclerosis: A progressive autoimmune disorder affecting the central nervous system resulting in demyelination. Patients develop physical and cognitive impairments that correspond with the affected nerve fibers.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
224 |
4. Check minimum number of eventsNone |
224 |
5. Include endpointsNone |
224 |
6. Filter based on genotype QC (FinnGen only) |
224 |
Control definitions (FinnGen only)
- Control exclude
- M13_SYSTCONNECT
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M35
- Name in latin
- Fibrosclerosis multifocalis
Similar endpoints
↥List of similar endpoints to
Multifocal fibrosclerosis
based on the number of shared cases.
Similar with more cases:
- Other systemic involvement of connective tissue
- Systemic connective tissue disorders
- Diseases of the musculoskeletal system and connective tissue
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1805 | 1278 | 511 |
| Only index persons | 1554 | 1106 | 448 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.04 | 0.01 |
| Only index persons | 0.03 | 0.04 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 72.13 | 72.44 | 71.18 |
| Only index persons | 70.74 | 71.06 | 69.95 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 224 | 151 | 73 |
| Unadjusted period prevalence (%) | 0.05 | 0.05 | 0.03 |
| Median age at first event (years) | 63.18 | 61.22 | 67.24 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 201
- Matched controls
- 2009
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M35.5
ICD-10 Finland
Multifocal fibrosclerosis
+∞
291.0
201
*
M35.3
ICD-10 Finland
Polymyalgia rheumatica
191.6
122.9
119
15
H02AB06
ATC
prednisolone; systemic
8.4
38.3
163
679
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
9.9
33.0
73
109
M35.9
ICD-10 Finland
Systemic involvement of connective tissue, unspecified
+∞
29.9
28
*
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
310.3
27.4
27
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
5.2
26.7
134
557
M31.5
ICD-10 Finland
Giant cell arteritis with polymyalgia rheumatica
271.0
24.2
24
*
L04AX03
ATC
methotrexate; systemic (immunosuppressants)
8.5
22.8
53
81
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
10.9
20.9
41
46
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
8.7
20.4
46
66
P01BA02
ATC
hydroxychloroquine; oral
8.1
20.2
48
75
H02AB07
ATC
prednisone; oral
5.1
18.3
66
176
PAW37
NOMESCO Finland
Biopsy of temporal artery
196.6
17.8
18
*
L88
ICPC
Rheumatoid/seropositive arthritis
12.0
16.9
31
30
M35.1
ICD-10 Finland
Other overlap syndromes
+∞
16.9
16
*
M05BA04
ATC
alendronic acid; oral
4.7
12.6
46
120
M25.5
ICD-10 Finland
Pain in joint
3.2
12.2
83
364
N03AX16
ATC
pregabalin; oral
3.2
11.5
76
323
N02AX02
ATC
tramadol; systemic, rectal
2.8
10.9
109
599
M79.1
ICD-10 Finland
Myalgia
4.1
10.2
42
122
M06.9
ICD-10 Finland
Rheumatoid arthritis, unspecified
9.5
10.1
20
23
L04AX01
ATC
azathioprine; systemic
7.8
9.8
22
31
M13.9
ICD-10 Finland
Arthritis, unspecified
5.2
9.6
30
66
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
2.6
9.5
112
661
R70.0
ICD-10 Finland
Elevated erythrocyte sedimentation rate
11.5
9.5
17
16
A02BC02
ATC
pantoprazole; systemic
2.8
9.5
155
1097
NK6QA
NOMESCO Finland
Measurement of bone density from tow or more locations with X-ray
5.4
9.4
28
58
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.5
9.1
111
659
M05BA07
ATC
risedronic acid; oral
6.8
8.6
21
34
H04.10
ICD-10 Finland
Dry eye syndrome
4.1
8.5
33
91
M35.7
ICD-10 Finland
Hypermobility syndrome
+∞
8.4
8
*
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
2.4
8.3
108
653
H02AB04
ATC
methylprednisolone; systemic
3.1
7.8
46
175
M01AE02
ATC
naproxen; oral, rectal
2.3
7.6
124
823
J01DB01
ATC
cefalexin; oral
2.9
7.6
172
1357
L01BA01
ATC
methotrexate; systemic (folic acid analog.)
6.0
7.6
20
36
A07EC01
ATC
sulfasalazine; oral, rectal
4.2
7.3
27
71
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
2.8
7.3
51
219
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.2
7.1
39
141
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
4.6
7.1
24
58
M03BC51
ATC
orphenadrine, combinations; systemic
2.5
7.1
67
338
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
3.7
7.0
30
91
J01FA10
ATC
azithromycin; systemic
2.2
6.8
118
792
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
3.7
6.7
29
88
A46
ICD-10 Finland
Erysipelas
2.9
6.6
42
169
M54.5
ICD-10 Finland
Low back pain
2.3
6.6
81
462
NB1AA
NOMESCO Finland
Shoulder X-ray examination without contrast
4.3
6.4
23
59
M79.7
ICD-10 Finland
Fibromyalgia
6.7
6.3
15
24
H35.5
ICD-10 Finland
Hereditary retinal dystrophy
+∞
6.3
6
*
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
2.2
6.2
85
506
J45.9
ICD-10 Finland
Asthma, unspecified
2.6
6.1
49
223
R07.4
ICD-10 Finland
Chest pain, unspecified
2.3
6.1
69
377
R50.9
ICD-10 Finland
Fever, unspecified
2.9
6.1
38
151
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
84
271
4.36
23.80
1.3
1.3
10.4
16.4
u/ml
0.42
23
99
85
290
4.11
22.10
1.5
1.2
36.3
42.1
iu/ml
0.18
27
94
115
576
3.05
15.13
3.3
2.0
402.9
215.3
u/l
0.32
102
538
168
1059
3.35
14.35
14.3
8.8
4.6
4.2
e9/l
1.64
152
919
147
909
2.80
12.06
4.8
4.0
0.0
0.0
estimate
0.00
39
181
152
957
2.83
12.03
7.7
6.1
1.2
1.2
mmol/l
0.41
134
799
191
1368
3.69
11.87
13.0
3.8
14.1
13.3
mm/h
0.30
178
1241
144
893
2.72
11.55
4.7
4.0
0.0
0.0
estimate
0.00
34
191
144
901
2.68
11.21
6.1
5.3
0.0
0.0
estimate
0.00
38
186
45
152
3.45
11.19
1.8
2.9
65.9
66.4
g/l
0.15
40
133
92
469
2.63
10.88
2.8
2.7
3835.1
10470.3
umol/l
0.83
81
386
23
51
4.91
10.03
1.5
1.4
0.0
0.0
iu/ml
—
5
12
27
70
4.25
9.73
1.4
2.5
3.4
3.1
g/l
0.41
20
52
125
775
2.39
9.28
3.3
2.2
83.2
77.8
nmol/l
1.56
119
673
17
31
5.85
9.12
1.1
1.2
—
—
—
0
0
136
881
2.38
9.05
6.8
5.6
1.2
1.2
mmol/l
0.14
126
796
24
62
4.22
8.67
1.3
2.6
37.3
37.8
g/l
0.14
19
49
27
77
3.85
8.55
1.4
2.4
3.5
3.8
g/l
0.51
20
50
27
77
3.85
8.55
1.4
2.4
—
—
—
0
0
27
77
3.85
8.55
1.4
2.4
7.4
7.4
g/l
0.03
21
53
19
41
4.97
8.52
1.9
1.3
—
—
—
0
0
131
851
2.30
8.44
4.9
4.0
34.8
34.9
g/l
0.04
120
790
189
1448
2.95
8.41
12.0
6.9
76.8
79.9
u/l
0.34
179
1343
61
290
2.52
8.00
3.2
2.8
3.2
2.7
e6/l
0.15
42
152
57
266
2.53
7.76
2.8
2.3
22.2
21.4
%
0.17
52
235
104
632
2.21
7.67
3.2
3.3
1615.0
1744.3
ng/l
0.12
90
537
86
486
2.25
7.57
2.5
2.1
3.2
3.3
mg/l
0.23
68
412
33
118
3.11
7.38
1.5
1.7
—
—
—
0
0
120
786
2.13
7.17
2.5
2.0
90.8
95.4
pmol/l
0.57
63
378
37
151
2.74
6.52
4.1
3.2
77.7
87.6
ng/l
0.47
32
130
16
39
4.34
6.20
1.4
1.4
—
—
—
0
0
103
663
2.02
6.19
2.7
3.1
2.4
2.4
mmol/l
0.02
87
577
66
361
2.17
6.11
4.8
3.6
74.9
150.9
ng/l
0.58
53
293
138
1004
1.98
5.66
5.4
5.8
9.7
10.9
umol/l
1.67
127
944
176
1405
2.18
5.46
5.2
4.1
15.3
14.9
pmol/l
0.96
157
1244
103
689
1.92
5.33
4.6
3.1
—
—
—
0
0
92
594
1.93
5.28
2.8
2.3
69.6
55.5
u/l
0.89
83
539
59
327
2.09
5.19
1.9
1.8
—
—
—
0
0
112
779
1.88
5.06
3.4
2.6
110.0
121.6
ug/l
0.33
101
706
21
72
3.11
5.02
1.9
2.0
33.5
39.4
u/l
0.76
21
62
66
387
2.00
4.96
2.9
3.0
2.5
2.5
mmol/l
0.05
53
341
84
539
1.89
4.83
4.3
3.0
0.2
0.6
e6/l
2.11
71
404
15
43
3.67
4.70
1.1
1.1
—
—
—
0
0
145
1115
1.85
4.57
6.0
4.5
6.8
6.7
mmol/l
0.18
139
1033
207
1814
2.86
4.49
30.7
15.0
18.1
23.5
mg/l
2.25
181
1450
9
13
7.16
4.20
1.3
1.1
—
—
—
0
0
9
13
7.16
4.20
1.3
1.1
—
—
—
0
0
9
13
7.16
4.20
1.3
1.1
—
—
—
0
0
9
13
7.16
4.20
1.3
1.1
—
—
—
0
0
9
13
7.16
4.20
1.3
1.1
—
—
—
0
0
16
52
3.24
4.17
1.1
1.3
—
—
—
0
0
54
312
1.96
4.17
3.3
2.6
1.1
1.3
e6/l
0.13
35
172
51
290
1.98
4.12
3.1
3.2
0.8
0.8
mmol/l
0.23
46
271
42
225
2.07
3.99
1.9
1.7
—
—
—
0
0
65
407
1.84
3.92
1.8
1.6
1.5
1.3
mg/l
0.14
52
326
65
410
1.82
3.82
1.8
1.7
1125.2
1221.7
nmol/l
0.35
53
304
30
144
2.25
3.74
5.8
5.6
9.7
10.0
mmol/l
0.13
30
134
42
231
2.01
3.71
1.9
1.8
—
—
—
0
0
13
40
3.39
3.68
1.1
1.1
—
—
—
0
0
14
46
3.18
3.59
1.5
1.5
—
—
—
0
0
191
1664
2.00
3.42
6.7
4.9
1.7
2.0
mu/l
4.02
175
1484
60
383
1.77
3.35
1.4
1.2
1.2
1.8
u/ml
0.43
12
108
33
174
2.05
3.26
2.8
2.3
29.3
29.0
u/l
0.04
26
144
10
28
3.69
3.23
1.1
1.0
—
—
—
0
0
8
15
5.49
3.22
1.0
1.1
—
—
—
0
0
7
11
6.53
3.21
1.6
1.2
—
—
—
0
0
65
430
1.72
3.19
2.4
2.2
—
—
—
0
0
8
16
5.14
3.08
1.1
1.0
—
—
—
0
0
124
979
1.60
2.97
2.9
2.7
—
—
—
0
0
69
479
1.64
2.78
2.0
1.5
22.2
21.4
nmol/l
0.16
59
393
135
1102
1.57
2.70
3.2
3.0
42.9
49.5
u/l
0.80
125
1021
27
142
2.02
2.70
2.0
1.5
—
—
—
0
0
73
520
1.60
2.64
5.3
4.2
0.0
0.0
estimate
0.00
38
178
96
729
1.55
2.63
4.6
4.1
—
—
—
0
0
22
109
2.13
2.56
4.2
3.4
1.7
2.5
mmol/l
0.49
15
86
5
7
7.27
2.56
1.2
1.3
593.4
1057.9
u/ml
—
5
7
6
11
5.57
2.56
1.0
1.0
—
—
—
0
0
13
51
2.64
2.49
1.6
1.2
—
—
—
0
0
204
1872
2.01
2.35
26.6
18.0
139.8
139.7
mmol/l
0.13
196
1816
6
13
4.71
2.28
1.0
1.0
—
—
—
0
0
107
851
1.49
2.28
5.2
4.0
—
—
—
0
0
28
159
1.87
2.26
2.7
2.9
177.9
262.8
ng/l
0.63
23
143
204
1877
1.97
2.25
26.9
18.1
4.0
4.0
mmol/l
0.85
195
1818
5
9
5.65
2.22
1.0
1.6
—
—
—
0
0
11
42
2.70
2.22
1.5
1.3
—
—
—
0
0
11
42
2.70
2.22
1.5
1.3
—
—
—
0
0
30
177
1.80
2.16
2.2
2.5
7.7
4.9
ug/l
0.45
22
151
14
62
2.34
2.12
1.9
5.3
1.2
3.1
ratio
—
5
8
8
25
3.28
2.11
1.1
1.3
—
—
—
0
0
187
1687
1.66
2.09
25.2
14.9
75.5
76.2
ml/min/173m2
0.16
167
1378
36
228
1.69
2.04
7.9
5.8
2.2
1.5
mmol/l
0.52
28
180
17
85
2.08
1.96
3.3
3.5
24.7
24.6
mmol/l
0.08
17
78
5
11
4.62
1.95
1.0
1.0
—
—
—
0
0
16
79
2.10
1.90
1.9
2.0
—
—
—
0
0
41
274
1.61
1.89
25.0
24.5
1.8
1.3
inr
—
5
29
7
22
3.25
1.89
1.0
1.0
—
—
—
0
0
6
17
3.60
1.85
1.0
1.1
—
—
—
0
0
7
23
3.11
1.81
1.1
1.0
—
—
—
0
0
203
1896
1.75
1.67
30.9
18.0
82.4
77.7
umol/l
1.05
203
1896
6
20
3.05
1.59
1.0
1.1
—
—
—
0
0
10
44
2.33
1.55
1.2
1.4
—
—
—
0
0
7
27
2.64
1.52
1.3
1.2
—
—
—
0
0
9
37
2.49
1.49
1.3
1.7
—
—
—
0
0
14
74
1.95
1.42
1.8
1.9
—
—
—
0
0
202
1903
1.63
1.36
19.5
10.3
25.9
23.6
u/l
0.95
194
1825
18
108
1.72
1.26
1.1
1.2
28.5
120.8
iu/ml
—
6
43
96
812
1.32
1.22
5.6
4.2
25.5
42.6
ng/l
1.75
71
586
5
19
2.67
1.22
1.0
1.1
—
—
—
0
0
207
1971
1.66
1.20
40.8
22.5
130.1
132.4
g/l
1.62
202
1930
182
1691
1.41
1.18
7.6
6.1
41.7
40.6
mmol/mol
0.85
166
1553
187
1752
1.41
1.10
5.8
4.8
5.8
6.0
mmol/l
1.26
171
1571
9
49
1.87
1.00
1.1
1.5
—
—
—
0
0
10
55
1.86
0.93
2.1
1.5
—
—
—
0
0
6
28
2.17
0.92
1.8
1.6
—
—
—
0
0
179
1680
1.33
0.91
4.6
4.1
1.3
1.2
mmol/l
0.91
162
1500
8
42
1.94
0.89
1.4
1.4
27.6
22.4
iu/l
—
8
35
6
113
0.52
0.85
1.5
1.8
—
—
—
0
0
0
25
0.00
0.79
0.0
1.2
—
—
—
0
0
11
67
1.67
0.76
2.2
2.3
—
—
—
0
0
167
1568
1.26
0.75
28.5
16.2
38.6
39.0
%
0.25
122
1056
5
24
2.11
0.75
1.2
1.7
—
—
—
0
0
5
24
2.11
0.75
1.2
1.7
—
—
—
0
0
5
24
2.11
0.75
1.2
1.7
—
—
—
0
0
17
117
1.49
0.74
1.6
1.4
—
—
—
0
0
5
25
2.02
0.73
2.0
1.6
—
—
—
0
0
22
161
1.41
0.71
1.5
1.7
1.6
1.4
%
1.15
22
135
184
1751
1.28
0.71
5.1
4.6
4.6
4.6
mmol/l
0.08
172
1588
183
1741
1.28
0.70
5.1
4.6
1.5
1.5
mmol/l
1.15
170
1567
7
44
1.61
0.65
1.7
1.5
—
—
—
0
0
33
264
1.29
0.63
1.4
1.4
—
—
—
0
0
12
81
1.51
0.58
2.5
1.9
1.1
4.8
ug/l
0.50
12
69
55
474
1.21
0.56
1.5
1.6
1.5
1.3
mmol/l
0.70
48
391
9
60
1.52
0.55
1.3
1.2
—
—
—
0
0
9
61
1.50
0.54
1.3
1.2
—
—
—
0
0
50
429
1.21
0.54
1.7
1.8
448.8
471.4
pmol/l
0.17
42
358
7
47
1.50
0.48
1.7
1.5
—
—
—
0
0
51
444
1.19
0.47
4.9
5.5
2.3
2.9
ug/l
0.29
45
385
19
148
1.31
0.45
4.0
3.0
57.4
63.1
ml/min/173m2
—
7
60
186
1798
1.20
0.44
5.7
5.2
2.7
2.7
mmol/l
0.20
174
1618
12
87
1.40
0.43
1.1
1.0
—
—
—
0
0
0
19
0.00
0.39
0.0
1.4
—
—
—
0
0
26
218
1.22
0.36
1.9
4.1
3.8
38.8
ug/l
0.60
18
185
7
56
1.26
0.29
1.1
1.5
—
—
—
0
0
26
224
1.18
0.28
3.1
3.7
—
—
—
0
0
11
88
1.26
0.23
2.3
1.3
—
—
—
0
0
5
42
1.19
0.21
1.2
1.8
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
1.4
—
—
—
0
0
0
12
0.00
0.21
0.0
2.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
0
14
0.00
0.20
0.0
1.5
—
—
—
0
0
6
49
1.23
0.20
1.5
1.3
—
—
—
0
0
6
50
1.21
0.20
1.5
1.3
—
—
—
0
0
37
349
1.07
0.10
3.3
4.9
17.2
21.5
%
1.54
18
181
22
238
0.92
0.10
10.0
7.3
—
—
—
0
0
10
114
0.87
0.09
2.7
2.1
—
—
—
0
0
25
268
0.92
0.09
1.6
1.4
—
—
—
0
0
27
253
1.08
0.09
3.1
3.1
0.9
0.8
ug/l
0.23
18
168
11
103
1.07
0.02
2.5
2.0
—
—
—
0
0
10
107
0.93
0.02
1.8
2.5
1.2
1.1
%
—
10
107
0
5
0.00
0.00
0.0
1.0
—
1.2
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
2.0
—
—
—
0
0
6
60
1.00
0.00
2.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
2.1
—
13.7
—
0
9
Mortality – FinRegistry
↥Association
Association between endpoint M13_MULTIFIBRO and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_MULTIFIBRO | 1.619 [1.38, 1.9] | < 0.001 |
| Birth year | 0.99 [0.98, 1.0] | 0.019 |
During the follow-up period (1.1.1998 — 31.12.2019), 528 out of 1187 females with M13_MULTIFIBRO died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_MULTIFIBRO | 1.371 [1.09, 1.72] | 0.006 |
| Birth year | 0.988 [0.98, 1.0] | 0.015 |
During the follow-up period (1.1.1998 — 31.12.2019), 229 out of 481 males with M13_MULTIFIBRO died.
Mortality risk
Mortality risk for people of age
years, who have M13_MULTIFIBRO.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.105% | 0.27% |
| 5 | 0.745% | 1.63% |
| 10 | 1.866% | 3.975% |
| 15 | 3.45% | 7.504% |
| 20 | 6.278% | 13.11% |
Relationships between endpoints
↥Index endpoint: M13_MULTIFIBRO – Multifocal fibrosclerosis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data